Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy

Sofie De Langhe1, Thomas Mulliez2, Liv Veldeman2, Vincent Remouchamps3, Annick van Greveling2, Monique Gilsoul3, Eline De Schepper1, Kim De Ruyck1, Wilfried De Neve2 and Hubert Thierens1*

Abstract

Background: After breast-conserving radiation therapy most patients experience acute skin toxicity to some degree. This may impair patients’ quality of life, cause pain and discomfort. In this study, we investigated treatment and patient-related factors, including genetic polymorphisms, that can modify the risk for severe radiation-induced skin toxicity in breast cancer patients.

Methods: We studied 377 patients treated at Ghent University Hospital and at ST.-Elisabeth Clinic and Maternity in Namur, with adjuvant intensity modulated radiotherapy (IMRT) after breast-conserving surgery for breast cancer. Women were treated in a prone or supine position with normofractionated (25 × 2 Gy) or hypofractionated (15 × 2.67 Gy) IMRT alone or in combination with other adjuvant therapies. Patient- and treatment-related factors and genetic markers in regulatory regions of radioresponsive genes and in LIG3, MLH1 and XRCC3 genes were considered as variables. Acute dermatitis was scored using the CTCAEv3.0 scoring system. Desquamation was scored separately on a 3-point scale (0-none, 1-dry, 2-moist).

Results: Two-hundred and twenty patients (58%) developed G2+ dermatitis whereas moist desquamation occurred in 56 patients (15%). Normofractionation (both p < 0.001), high body mass index (BMI) (p = 0.003 and p < 0.001), bra cup size ≥ D (p = 0.001 and p = 0.043) and concurrent hormone therapy (p = 0.001 and p = 0.037) were significantly associated with occurrence of acute dermatitis and moist desquamation, respectively. Additional factors associated with an increased risk of acute dermatitis were the genetic variation in MLH1 rs1800734 (p=0.008), smoking during RT (p = 0.010) and supine IMRT (p = 0.004). Patients receiving trastuzumab showed decreased risk of acute dermatitis (p < 0.001).

Conclusions: The normofractionation schedule, supine IMRT, concomitant hormone treatment and patient related factors (high BMI, large breast, smoking during treatment and the genetic variation in MLH1 rs1800734) were associated with increased acute skin toxicity in patients receiving radiation therapy after breast-conserving surgery. Trastuzumab seemed to be protective.

Keywords: Acute skin toxicity, Breast cancer, Genetic polymorphisms, Large breast size, Radiotherapy
Background

Breast-conserving therapy with the adjuvant use of radiotherapy (RT) has gained an established role in the treatment for early-stage breast cancer with excellent long-term local control and survival [1]. During or shortly after the course of breast cancer RT, a large portion of the patients will experience acute radiation dermatitis to some degree, varying from mild to brisk erythema with or without moist desquamation and occasionally ulceration of the skin [2]. There is accumulating clinical evidence that acute reactions are associated with the development of late toxicity: Lilla et al. showed that telangiectasia are in fact late sequelae of moist desquamation and acute erythema is shown to be a risk factor for poor cosmetic outcome [3-5]. Though the skin is not a dose-limiting tissue, skin toxicity is associated with impairment of patients’ quality of life, causes pain and discomfort and limits activities [2,6]. The challenge is to minimize these side effects without losing efficacy of the treatment.

Over the years, many attempts have been made to reduce the number of patients experiencing acute skin toxicity and inferior cosmetic outcome by introducing improved radiation techniques, such as intensity-modulated radiotherapy (IMRT). This technique has been shown to be superior over conventional wedge-based whole breast irradiation by delivering a more homogenous dose through the breast and removing the radiation hot spots: it results in an approximately 20% reduction of the frequency of moist desquamation [6,7]. Large breast size significantly contributes to dose inhomogeneity, hot spots and toxicity [7,8]. The variation in clinical response is, however, only partly explained by treatment factors such as radiation dose, fractionation scheme, and concomitant therapies. Patient-related features (e.g. bra cup size and body mass index (BMI)) also play a role together with an unknown contribution from genetic factors. Up to now there are no data available to estimate directly the heritability of clinical radiosensitivity based upon family history of radiotherapy toxicity, but it is likely to be somewhat lower than for chromosomal and cellular radiosensitivity, which have been calculated to be 58-78% [9].

Acute toxicity is initiated by depletion of acutely responding epithelial tissues and damage to microvessels [10]. Numerous studies have reported on genetic variations modifying the clinical radiosensitivity risk, predominantly in pathways based on mechanistic understanding of the radiation pathogenesis (reviewed in [11]). In the present study, single nucleotide polymorphisms (SNPs) in genes involved in major DNA repair pathways (LIG3, XRC33, MLH1) and in regulatory regions that influence the expression levels of radioresponsive genes are considered [12-16].

To gain a better insight into the development of radiation-induced dermatitis and moist desquamation, we evaluated the association between patient and treatment features with these endpoints. The association between SNPs and the different clinical endpoints was also studied.

Methods

The study population consists of 377 breast cancer patients treated with adjuvant IMRT with curative intent after breast-conserving surgery (stage T1-3, N0-1, M0). Of them, 282 breast cancer patients were treated at the Ghent University Hospital (GUH) and 95 patients were treated at ST.-Elisabeth Clinic and Maternity (CMSE) in Namur. Patients’ follow-up ranged from 1 month after the end of RT to 41 months after the end of RT (median = 18 months).

At GUH, patients were treated in prone or supine position using a multi-beam IMRT technique in supine position and a tangential 2-beam field-in-field IMRT technique in prone position as described previously [17]. The whole breast was treated with hypofractionated radiotherapy (40.05 Gy in 15 fractions [18]) with 6-MV photons of an Elekta Synergy linear accelerator (Crawley, United Kingdom). An additional photon boost of 10 Gy in 4 fractions to the tumour bed was given to 75% of the patients. For the prone patient setup, a unilateral breast holder (Van De Velde, Schellebelle, Belgium) and a prone breast board (Orfit Industries) were used [19]. Twenty-two patients were treated in prone position with voluntary moderate deep inspiration breath hold. At CMSE Namur, a sliding window tangential field-IMRT technique was used associated with moderate deep inspiration breath hold whenever the primary beam intersected the heart as previously described by Remouchamps et al. [20]. Patients with self-reported bra cup size ≥D received hypofractionated radiotherapy (50.00 Gy in 25 fractions), women with bra cup size <D received hypofractionation or normofractionation according to the preference of the radiation oncologist (n = 28). More than 90% received an additional boost of 10 Gy in 4 fractions with electron beams. Nodal irradiation was performed by a complex multi-beam IMRT or arc technique at GUH, at CMSE Namur, a one point setup with 4 beams with dynamic intensity modulation in the beams was used.

Adjuvant systemic therapy

Adjuvant hormone therapy, consisting of tamoxifen or aromatase inhibitors, was administered in most patients concomitantly with IMRT. The others received hormone therapy sequentially after IMRT. Patients who received adjuvant chemotherapy, combination of antracyclines and taxanes, completed chemotherapy before IMRT, while trastuzumab was allowed concomitantly with IMRT.

Data collection

Data on patients’ medical history, tumor and treatment characteristics were collected prospectively. Table 1 gives
Acute toxicity was assessed weekly during treatment and at 1–2 weeks after treatment. The reported toxicity represents the maximal reported acute toxicity, either during or after completion of IMRT. Acute dermatitis was documented according to a standard protocol using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 scoring system. This grades patients with mild erythema or dry desquamation as 1, moderate to brisk erythema or patchy moist desquamation mostly confined to the skin folds as 2 and confluent moist desquamation as 3. Desquamation was scored separately on a 3-point scale (0-none, 1-dry, 2-moist). Grade 2–3 toxicity was considered clinically relevant and was included in the analysis. Genomic DNA was isolated from a fresh blood sample taken before start of radiotherapy, using the Puregene genomic DNA purification kit (Gentra Systems, Minneapolis, MN). The study was approved by the local

| Table 1 Patient characteristics for patients treated at GUH and CMSE Namur |
|---------------------------------------------------------------|
| GUH (n = 282) | CMSE Namur (n = 95) |
| Age (years) | | |
| Median | 57.5 | 59.0 |
| Range | 30-82 | 35-82 |
| Bra cup size | | |
| Small | | |
| A | 13 (4.6) | 3 (3.2) |
| B | 85 (30.2) | 33 (34.7) |
| C | 101 (35.8) | 34 (35.8) |
| Large | | |
| D | 53 (18.8) | 16 (16.8) |
| E | 16 (5.7) | 5 (5.3) |
| F | 7 (2.5) | 3 (3.2) |
| G + H | 2 (0.6) | 1 (1.0) |
| Missing | 5 | 0 |
| BMI | | |
| Median | 25.5 | 26 |
| Range | 16-50 | 16-38 |
| Missing | 2 | 0 |
| Menstruation | | |
| No | 235 (83.3) | 76 (80.0) |
| Yes | 45 (16.0) | 18 (18.9) |
| Missing | 2 | 1 |
| Smoking during RT | | |
| No | 244 (86.5) | 79 (83.2) |
| Yes | 35 (12.4) | 16 (16.8) |
| Missing | 3 | 0 |
| Diabetes | | |
| No | 254 (90.1) | 84 (88.4) |
| Yes | 22 (7.8) | 11 (11.6) |
| Missing | 6 | 0 |
| Hypertension | | |
| No | 196 (69.5) | 66 (69.5) |
| Yes | 81 (28.7) | 29 (30.5) |
| Missing | 5 | 0 |
| Fractionation | | |
| Normo | 0 | 45 (47.4) |
| Hypo | 282 | 50 (52.6) |
| Missing | 0 | 0 |
| Treatment position | | |
| Supine | 195 (69.1) | 95 (100.0) |
| Prone | 87 (30.9) | 0 |
| Missing | 0 | 0 |

**Table 1 Patient characteristics for patients treated at GUH and CMSE Namur (Continued)**

| GUH (n = 282) | CMSE Namur (n = 95) |
| Boost | | |
| No | 64 (22.7) | 7 (7.4) |
| Yes | 218 (77.3) | 88 (92.6) |
| Missing | 0 | 0 |
| Nodal irradiation | | |
| No | 241 (85.5) | 87 (80.6) |
| Yes | 41 (14.5) | 21 (19.4) |
| Missing | 0 | 0 |
| Hormonal therapy | | |
| No | 46 (16.3) | 25 (26.3) |
| Concomitant | 236 (83.7) | 7 (7.4) |
| Sequential (after IMRT) | 0 | 63 (66.3) |
| Missing | 0 | 0 |
| Chemotherapy | | |
| No | 188 (66.7) | 55 (57.9) |
| Yes | 94 (33.3) | 40 (42.1) |
| Missing | 0 | 0 |
| Trastuzumab | | |
| No | 257 (91.1) | 83 (87.4) |
| Yes | 25 (8.9) | 12 (12.6) |
| Missing | 0 | 0 |

**Abbreviations:** GUH Ghent University Hospital, CMSE ST.-Elisabeth Clinic and Maternity, BMI Body Mass Index.

Data are given as no. (%) unless otherwise indicated.
ethics committees (Ghent University Hospital EC 2009/424, EC 2009/184) and all study patients provided written informed consent.

**Selection of candidate genes/polymorphisms and genotyping**

Eight candidate polymorphisms were selected for genotyping (Table 2). Of these, five SNPs (rs3888929, rs4867592, rs7970524, rs12003093, rs4760658) were chosen as they putatively affect the expression levels of radiation-responsive genes directly, or by *trans* effects, based on genetic linkage and association analysis as described previously by Smirnov et al. The authors suggested that those regulatory variants might be able to contribute to the development of genetic tools for radiosensitivity [16]. The other SNPs were chosen based on their previous association with toxicity induced by radiotherapy or methylating agents (*XRCC3* rs861539, *LIG3* rs3744355, *MLH1* rs1800734) [12-15]. Genotyping was performed using restriction fragment length polymorphism analyses, high resolution melting curve analyses, single base extension techniques or direct sequencing. For reproducibility control, 15% of all samples were duplicated. The concordance rate between duplicate samples was 100%. Primers details are available on request. Tests for deviation from Hardy-Weinberg equilibrium, for the entire sample showed that the rs4867592 SNP had a p-value <0.0001 and was excluded from further analyses.

**Statistical analysis**

The studied endpoints were development of acute radiation-induced dermatitis (CTCAE G2+) and moist desquamation. For the clinical association analysis, univariate analysis was initially carried out to assess the relationship between patient- (age, bra cup size (A + B + C vs. ≥D), BMI, men- strutrition, smoking during RT, diabetes, hypertension) and treatment-related factors (fractionation scheme, treatment position, boost dose to tumour bed, nodal irradiation, hormone therapy, chemotherapy and trastuzumab) and the endpoints. Patients with and without G2+ acute skin toxicity were compared by means of the Mann–Whitney test for continuous variables and the χ²-test for categorical variables. Power calculations were performed with Power for Genetic Association analyses [21]. For these we took into account: the incidence of dermatitis (58%) or moist desquamation (15%) observed in our cohort, the lowest minor allele frequency (9%) of the considered SNPs, a probability adjusted by the number of SNPs (α = 6.25 × 10⁻³) under a dominant genotypic test, and a genotype relative risk of ≥1.5. This resulted in a power of 94.3% for acute dermatitis and 60.9% for moist desquamation. To assess the independent effect of each polymorphism, unconditional logistic regression analyses were performed to calculate crude ORs. The Benjamini-Hochberg (BH) procedure was used to control for multiple testing (i.e. 43 tests per endpoint: 28 genetic and 15 clinical parameter tests) to reduce the risk of finding false-positive associations. Variables with p < 0.05 were tested in a multivariate logistic regression analysis. Statistical analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, IL). R library *multtest* (http://www.r-project.org/) was used to perform the multiple testing analyses.

**Results**

Acute radiation-induced skin toxicity data were available for all 377 patients. Two-hundred twenty patients (58%) developed G2+ dermatitis. The occurrence of dermatitis did not differ between both centres (GUH: 57% (162/282), CSME: 61% (58/95)). Moist desquamation (patchy or confluent) occurred in 56 patients (15%) and differed between both centres: 10% of the patients treated at GUH and 30% of the patients treated at CMSE (p < 0.001).

**Acute radiation-induced skin toxicity**

Table 3 depicts the parameters associated with acute G2+ dermatitis, in univariate analysis. Bra cup size ≥ D (p < 0.001), BMI (p <0.001) and smoking during RT (p = 0.029) were associated with the development of G2+ dermatitis. Irradiation of the nodal region (p = 0.006) and

### Table 2: Characteristics of the SNPs

| Gene or gene regulator | rs number | MAF* | Nucleotide substitution | Genomic location | Amino acid substitution | Reference |
|------------------------|-----------|------|-------------------------|------------------|-------------------------|-----------|
| *LIG3*                 | rs3744355 | 9.1  | G > C                   | 5’-flanking       | -                       | [12,13]   |
| *MLH1*                 | rs1800734 | 22.6 | G > A                   | 5’-UTR           | -                       | [14]      |
| *XRCC3*                | rs861539  | 39.0 | C > T                   | Coding           | Thr241Met               | [15]      |
| PHLDA3                 | rs3888929 | 30.3 | G > A                   | Unknown          | -                       | [16]      |
| *LCP2*                 | rs4867592 | 19.1 | C > A                   | Unknown          | -                       | [16]      |
| *LTHA4*                | rs7970524 | 25.1 | T > C                   | 5’-flanking       | -                       | [16]      |
| *NDUFB6*               | rs12003093| 23.4 | A > G                   | Unknown          | -                       | [16]      |
| VDR                    | rs4760658 | 36.6 | A > G                   | Intronic         | -                       | [16]      |

*Minor allele frequency in Caucasian population.
the use of concomitant hormone therapy (p = 0.041) were also associated with an increased risk of acute dermatitis, with no difference in incidence between aromatase-inhibitors and tamoxifen. In contrast, patients receiving trastuzumab or having received chemotherapy seem to be less prone to the development of RT-induced acute dermatitis (p = 0.003 and p = 0.045, respectively). Furthermore, patients treated with hypofractionated radiotherapy develop less dermatitis when compared to patients treated in the normofractionated regimen (p < 0.001). And, patients treated in prone position developed less dermatitis than patients treated supine (p = 0.002). In multivariate analysis, chemotherapy and nodal irradiation were no longer significant (Table 4).

For moist desquamation, univariate significant associations were found with bra cup size ≥D (p < 0.001), BMI (p < 0.001), normofractionation (p < 0.001), supine positioning (p = 0.002), concurrent hormone therapy (p = 0.004) and CSME center (p < 0.001) (Table 5). In multivariate analysis (Table 6), bra cup size ≥D, BMI, fractionation and hormone therapy remained statistically significant. Treatment center was no longer significantly associated with moist desquamation due to the fact that the normofractionated schedule was only prescribed at CMSE.

### Table 3 Associations between patient- and therapy-related characteristics and acute G2+ dermatitis

|                      | All (n = 377) | G0-1 (n = 157) | G2+ (n = 220) | p-value | pBH-value |
|----------------------|---------------|----------------|---------------|---------|-----------|
| **Bra cup size**     |               |                |               |         |           |
| A + B + C            | 269 (71.4)    | 130 (48.3)     | 139 (51.7)    |         |           |
| ≥D                   | 103 (27.3)    | 26 (25.2)      | 77 (74.8)     | <0.001  | 0.001     |
| **BMI**              |               |                |               |         |           |
| Median               | 26            | 24             | 26            |         |           |
| Range                | 16-50         | 16-37          | 16-50         | <0.001  | 0.001     |
| **Smoking during RT**|               |                |               |         |           |
| No                   | 323 (85.7)    | 141 (43.7)     | 182 (56.3)    |         |           |
| Yes                  | 51 (13.5)     | 14 (27.5)      | 37 (72.5)     | 0.029   | 0.156     |
| **Fractionation**    |               |                |               |         |           |
| Normo                | 45 (11.9)     | 6 (13.3)       | 39 (86.7)     |         |           |
| Hypo                 | 332 (88.1)    | 151 (45.5)     | 181 (54.5)    | <0.001  | <0.001    |
| **Treatment position**|             |                |               |         |           |
| Supine               | 290 (76.9)    | 108 (37.2)     | 182 (62.8)    |         |           |
| Prone                | 87 (23.1)     | 49 (56.3)      | 38 (43.7)     | 0.002   | 0.019     |
| **Nodal irradiation**|               |                |               |         |           |
| No                   | 315 (83.6)    | 141 (44.8)     | 174 (55.2)    |         |           |
| Yes                  | 62 (16.4)     | 16 (25.8)      | 46 (74.2)     | 0.006   | 0.037     |
| **Hormonal therapy**|               |                |               |         |           |
| No                   | 71 (18.8)     | 39 (54.9)      | 32 (45.1)     |         |           |
| Concomitant          | 243 (64.5)    | 94 (38.7)      | 149 (61.3)    |         |           |
| Sequential (after IMRT) | 63 (16.7)  | 24 (38.1)      | 39 (61.9)     | 0.041   | 0.207     |
| Hormones (concomitant) |             |                |               |         |           |
| Tamoxifen            | 155           | 62 (40.0)      | 93 (60.0)     |         |           |
| Aromatase inhibitor  | 85            | 32 (37.6)      | 53 (62.4)     |         |           |
| **Chemotherapy**     |               |                |               |         |           |
| No                   | 243 (64.5)    | 92 (37.9)      | 151 (62.1)    |         |           |
| Yes                  | 134 (35.5)    | 65 (48.5)      | 69 (51.5)     | 0.045   | 0.215     |
| **Trastuzumab**      |               |                |               |         |           |
| No                   | 340 (90.2)    | 133 (39.1)     | 207 (60.9)    |         |           |
| Yes                  | 37 (9.8)      | 24 (64.9)      | 13 (35.1)     | 0.003   | 0.026     |

Abbreviations: G = CTCAEv.3 grade, BMI = Body Mass Index; pBH = corrected p-value by Benjamini-Hochberg procedure. Data are given as no. (%) unless otherwise indicated. P<0.05 is considered significant and is showed in bold.
Table 4 Multivariate analysis for G2+ dermatitis and moist desquamation

| Clinical/genetic factor | Acute G2+ dermatitis | Moist desquamation |
|-------------------------|----------------------|--------------------|
|                         | OR   | p-value | OR   | p-value |
| Center (CMSE vs. GUH)   | -    | -       | 3.206 | 0.158   |
| BMI                     | 1.088| 0.003   | 1.170| <0.001  |
| Bra cup size (cup ≥ D vs. cup A + B + C) | 2.833| 0.001   | 2.146| 0.043   |
| Smoking (yes vs. no)    | 2.711| 0.010   | -    | -       |
| Fractionation (hypo vs. normo) | 0.083| <0.001  | 0.096| <0.001  |
| Treatment position (prone vs. supine) | 0.399| 0.004   | 0.373| 0.074   |
| Hormone therapy         |       |         |      |         |
| No                      | 1    | 1       | 1    | 1       |
| Concomitant             | 3.207| 0.001   | 4.770| 0.037   |
| Sequential (after IMRT) | 1.003| 0.994   | 1.078| 0.901   |
| Nodal irradiation (yes vs. no) | 1.975| 0.100   | -    | -       |
| Chemotherapy (yes vs. no) | 0.954| 0.877   | -    | -       |
| Trastuzumab (yes vs. no) | 0.177| <0.001  | -    | -       |
| MLH1 rs1800734 G > A    |      |         |      |         |
| GG                      | 1    | -       | -    | -       |
| GA                      | 0.492| 0.008   | -    | -       |
| AA                      | 0.537| 0.232   | -    | -       |

Abbreviations: GUH Ghent University Hospital, CMSE Clinic Maternity Sainte-Elisabeth, BMI Body Mass Index, MLH1 MutL protein homolog 1.
P<0.05 is considered significant and is showed in bold.

Table 5 Associations between patient- and therapy-related characteristics and moist desquamation

|                  | All patients | No (n = 321) | Yes (n = 56) | p-value | P_{BH}-value |
|------------------|--------------|--------------|--------------|---------|--------------|
| Bra cup size     |              |              |              |         |              |
| A + B + C        | 269 (71.4)   | 242 (90.0)   | 27 (10.0)    | <0.001  | 0.001        |
| ≥D               | 103 (27.3)   | 76 (73.8)    | 27 (26.2)    | <0.001  | <0.001       |
| BMI              |              |              |              |         |              |
| Median           | 26           | 25           | 29           | <0.001  | <0.001       |
| Range            | 16-50        | 16-40        | 21-50        | <0.001  | <0.001       |
| Fractionation    |              |              |              |         |              |
| Normo            | 45 (11.9)    | 22 (48.9)    | 23 (51.1)    | <0.001  | <0.001       |
| Hypo             | 332 (88.1)   | 299 (90.1)   | 33 (9.9)     | <0.001  | <0.001       |
| Treatment position |           |              |              |         |              |
| Supine           | 290 (76.9)   | 239 (82.4)   | 51 (17.6)    |         |              |
| Prone            | 87 (23.1)    | 82 (94.3)    | 5 (5.7)      | 0.002   | 0.019        |
| Hormonal therapy |              |              |              |         |              |
| No               | 71 (18.8)    | 62 (87.3)    | 9 (12.7)     |         |              |
| Concomitant      | 243 (64.5)   | 214 (88.1)   | 29 (11.9)    |         |              |
| Sequential (after IMRT) | 63 (16.7)| 45 (71.4)    | 18 (28.6)    | 0.004   | 0.029        |
| Hormones (concomitant) |       |              |              |         |              |
| Tamoxifen        | 155          | 139 (89.7)   | 16 (10.3)    |         |              |
| Aromatase inhibitor | 85        | 74 (87.1)    | 11 (12.9)    |         |              |

Abbreviations: GUH Ghent University Hospital, CMSE Clinic Maternity Sainte-Elisabeth, BMI Body Mass Index; P_{BH} = corrected p-value by Benjamini-Hochberg procedure.
Data are given as no. (%) unless otherwise indicated. P<0.05 is considered significant and is showed in bold.
Genetic analysis

The only significant p-value, in univariate analysis, was for acute radiation-induced dermatitis with the GA genotype of rs1800734 in the MLH1 gene with a BH-adjusted p-value of 0.029 (Table 6). Adjusting for above mentioned factors by multivariate regression analysis had no effect on the statistically significant association. None of the other SNPs had any effect on the risk of acute skin toxicity.

Discussion

This study was performed to analyze the influence of treatment and patient-related factors on the development of acute radiation-induced skin toxicity. Bra cup size, BMI, smoking, treatment position, choice of RT schedule and the administration of adjuvant therapies seem to contribute to the variability in radiation skin toxicity. Also, the MLH1 rs1800734 SNP was found to be significantly associated with the development of acute dermatitis. Our data support the hypothesis that acute toxicity does not increase with moderate hypofractionation [22]. In fact, the occurrence of acute skin toxicity was significantly higher among patients treated with normofractionation compared to the hypofractionated schedule. There are only few reports studying hypofractionation in overweighed or large-breasted patients [23,24]. We observe a 20% decrease in dermatitis and an even larger decrease (70%) in moist desquamation in large-breasted patients treated in supine position with hypofractionation compared to normofractionation (data not shown). Bra cup size and BMI were also confirmed as significant risk factors for the development of acute skin toxicity, in accordance with the majority of published reports [7,8,25-27]. Both are measures of breast volume as BMI was previously found to be strongly correlated with breast volume [27]. The association between larger breast volume and toxicity is thought to be due to dose inhomogeneity, high dose regions, and the bolus effect in the inframammary and axillary regions [8].

Table 6 Effect of MLH1 rs1800734 on radiotherapy acute skin reactions

| MLH1 rs1800734 | Acute G2+ dermatitis | Moist desquamation |
|---------------|----------------------|-------------------|
| G > A         |                      |                   |
| GG (n = 157)  | G0+1 (51.6)          | 81 (51.6)         | 0.55 0.005 0.033 |
|               | G2+ (n = 220)        | 146 (66.4)        | 0.94 0.889 0.936 |
| GA (n = 220)  | 64 (40.8)            | 110 (43.3)        | 1.35 0.600 0.860 |
|               | 60 (27.3)            | 14 (25.0)         |                   |
| AA (n = 220)  | 9 (5.7)              | 17 (5.3)          |                   |
|               | 12 (5.5)             | 4 (7.1)           |                   |
| Missing       | 3 (1.9)              | 5 (1.6)           | 0                  |
| GG vs. GA + AA (dominant) |                      |                   |
| G0-1 (n = 321) | No (n = 95)         | Yes (n = 95)      |                   |
| OR p-value    | pBH-value            |                  |
| 0.52          | 0.004                | 0.029             |
| 0.74          | 0.514                | 0.804             |
| 0.94          | 0.889                | 0.936             |

Abbreviations: MLH1 MutL protein homolog 1, pBH = corrected p-value by Benjamini-Hochberg procedure. Data are given as no. (%) unless otherwise indicated. P<0.05 is considered significant and is showed in bold.

De Langhe et al. BMC Cancer 2014, 14:711 http://www.biomedcentral.com/1471-2407/14/711

In this study, two types of adjuvant hormone therapy, tamoxifen or aromatase-inhibitors, were concurrently administered with radiotherapy to hormone receptor positive breast cancer patients. Present data show that use of hormone therapy is, regardless the type, associated with an increase in radiation-induced dermatitis. This is in accordance with a previous study investigating the effect of tamoxifen on acute skin reactions [26]. But in contrary with the COHORT randomized trial, that shows no difference between concurrent and sequential administration of letrozole; the latter was administered 3 weeks after RT when it is supposed that the radiosensitising effect of endocrine therapy is minimal [28]. Concurrent administration of trastuzumab and IMRT was found to be associated with lower rates of acute dermatitis in the present study. This finding needs to be put in perspective as it is in contradiction with the observation of a large randomized study that could not find a difference in acute toxicity [29]. Longer follow-up will be necessary to observe the effect of concurrent administration on cardiac toxicity.

Our study shows an association between the MLH1 rs1800734 SNP and lower rates of acute radiation-induced dermatitis: heterozygotes are less present in the G2+
dermatitis group. The SNP maps 93 base pairs upstream of the \textit{MLH1} transcription site in the core promoter, a region essential for maximum transcriptional activity [30]. The SNP was previously shown to be associated with acute myeloid leukemia after methylating chemotherapy for Hodgkin disease [15]. \textit{MLH1} gene encodes MutL protein homolog 1 which is involved in DNA mismatch repair. Suga et al. found statistically significant associations with rs3744355 in the 5’ flanking region of the \textit{LIG3} gene and acute radiation-induced skin reactions in the Japanese population and Murray et al. provided replicated evidence for this association in a European Caucasian population [12,13]. We, however, could not confirm this association. Smirnov et al. hypothesized that regulatory variants might be able to contribute to the development of genetic tools to predict for radiosensitivity [16]. This could not be demonstrated in our study population.

Radiation-induced dermatitis includes erythema, edema, dry and moist desquamation as symptoms of inflammation probably triggered by cell death [31]. One of the shortcomings in this study is the fact that erythema was not measured objectively with a colorimeter. As the CTCAE criteria are based on subjective scoring, the difference between mild, moderate and brisk erythema is observer-dependent. This probably explains the large number of patients developing G2+ acute dermatitis when compared to other reports. A strength of our investigation is the nearly complete data set for a relatively large number of patients enrolled. Furthermore, patient recruitment as well as clinical outcome data collection were carried out prospectively. Although the associations hold after correcting for multiple testing, the results of this study should be validated in an independent study.

**Conclusion**

A number of treatment and patient related factors are identified that modify the risk for the development of acute skin toxicity after whole-breast IMRT. Large bra cup, BMI, normofractionation and concomitant hormone therapy contribute to the development of moist desquamation. Patient related factors (high BMI, large breast, smoking during treatment and the genetic variation \textit{MLH1} rs1800734), choice of RT schedule and the administration of adjuvant therapies affect the development of radiodermatitis.

**Abbreviations**

BH: Benjamini-hochberg; BMI: Body mass index; CMSE: ST-Elisabeth Clinic and Maternity; CTCAE: Common terminology criteria for adverse events; GUH: Ghent University Hospital; IMRT: Intensity-modulated radiotherapy; RT: Radiotherapy; SNP: Single nucleotide polymorphism.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

SDL participated in conception and design, the acquisition, performed the statistical analysis and interpretation of the data and drafted the manuscript. TM, LV, VR, AVG, MG and WDN participated in acquisition of the data. EDS carried out the genotyping work and helped in the statistical analysis. KDR, WDN and HT participated in the conception and design. All authors critically revised the manuscript and approved the final manuscript.

**Acknowledgments**

This work was supported by the Cancer Plan, Action 29 project 015, financed by the Federal Office of Health and Social Affairs, Belgium. We wish to thank Christian Defrese for his help with the toxicity recording and all study participants.

**Author details**

1. Department of Basic Medical Sciences, Ghent University, Proeftuinstraat 86, 9000 Ghent, Belgium. 2. Department of Radiotherapy, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. 3. Department of Radiotherapy, Clinique et Maternite St Elisabeth, Place Louise Godin, 15, 5000 Namur, Belgium.

Received: 28 October 2013 Accepted: 18 September 2014 Published: 25 September 2014

**References**

1. Early Breast Canc Trialists C: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011, 378(9804):1707–1716.
2. Feight D, Barney T, Bruce S, McQuestion M: Putting evidence into practice: evidence-based interventions for radiation dermatitis. Clin J Oncol Nurs 2011, 15(5):481–492.
3. Tanteles GA, Whitworth J, Mills J, Peat I, Osman A, McCann GP, Chan S, Banwell JG, Talbot CJ: Symonds RP: Can cutaneous telangiectasias as late normal-tissue injury predict cardiovascular disease in women receiving radiotherapy for breast cancer? Br J Cancer 2009, 101(3):403–409.
4. Lilla C, Ambrosone CB, Kropp S, Helmbold I, Schmezer P, von Fournier D, Haase W, Saufter-Bihl ML, Wenz F, Chang-Claude J: Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Cancer Res Treat 2007, 106(1):143–150.
5. Keller LMM, Sopka DM, UT TY, Klawon T, LI JS, Anderson PR, Bleicher RJ, Sigurdson ER, Freedman GM: Five-year results of whole breast intensity-modulated radiation therapy for the treatment of early stage breast cancer: the fox chase cancer center experience. Int J Radiat Oncol Biol Phys 2012, 84(4):881–887.
6. Pignol JP, Ollivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, Yu TTT, Truong P, Ackerman I, Pazat L: A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008, 26(15):2085–2092.
7. Freedman GM, Anderson PR, LI JS, Eisenberg DF, Hanlon AL, Wang L, Nicolaou N: Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol-Cancer Clinical Trials 2006, 29(1):66–70.
8. Moody AM, Mayes WPM, Bliss JM, Ahern RP, Owen JR, Regan J, Broad B, Yanroll JR: The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. Radiother Oncol 1994, 33(2):106–112.
9. Talbot CJ, Tanteles GA, Barnett GC, Bumet NG, Chang-Claude J, Coles CE, Davidson S, Dunnng AM, Mills J, Murray RJF, Popandou P, Seibold P, West CML, Yanroll JR, Symonds RP: A replicated association between polymorphisms near TNF alpha and risk for adverse reactions to radiotherapy. Br J Cancer 2012, 107(4):748–753.
10. Kim JH, Kaloszvay AJ, Jerens KA, Brown SL: Mechanisms of radiation-induced skin injury and implications for future clinical trials. Int J Radiat Biol 2013, 89(5):311–318.
11. Rosenberg BS: Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. Pharmacogenomics 2011, 12(2):267–275.
12. Murray RJ, Tanteles GA, Mills J, Perry A, Peat I, Osman A, Chan S, Cheung RL, Chakraborti PK, Woodings PL, Banwell JG, Symonds RP, Talbot CJ: Association between single nucleotide polymorphisms in the DNA repair
gene LIG3 and acute adverse skin reactions following radiotherapy. Radiother Oncol 2011, 99(2):231–234.

13. Suga T, Ishikawa A, Kohda M, Otsuka Y, Yamada S, Yamamoto N, Shibamoto Y, Ogawa Y, Nomura K, Shi K, Omura M, Sekiguchi K, Kikuchi Y, Michikawa Y, Noda S, Sagara M, Ohashi Y, Yoshinaga S, Masaie J, Tsutii H, Iwakawa M, Imag J: Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 2007, 69(3):685–693.

14. Werbrouck J, De Ruick K, Duprez F, Veldeman L, Claes K, Van Eijkeren M, Boterberg T, Willems P, Vral A, De Neve W, Thiérens H: Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA Dsb repair genes. Int J Radiat Oncol Biol Phys 2001, 50(4):1187–1195.

15. Worrillow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, Gilmeil B, Holowaty E, Jackson GH, Jones GL, Lynch CF, Morgan G, Pukkala E, Scott D, Storm HH, Taylor PR, Vyberg M, Willett E, Travis LB, Allen JM: Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet 2008, 45(3):142–146.

16. Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG: Genetic analysis of radiation-induced changes in human gene expression. Nature 2009, 459(7246):587–U120.

17. Mullee T, Speleers B, Madani I, De Gerssen W, Veldeman L, De Neve W: Whole breast radiotherapy in prone and supine position: is there a place for multi-beam IMRT? Radiat Oncol 2013, 8:151.

18. Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan D, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR, Start Trialists G: The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008, 371(9618):1098–1107.

19. Mullee T, Veldeman L, van Greveling A, Speleers B, Sadeghi S, Bervouts D, Decoster F, Vercauteren T, De Gerssen W, Van den Broecke B, De Neve W: Hypofractionated whole breast irradiation for patients with large breasts: A randomized trial comparing prone and supine positions. Radiat Oncol 2013, 108(2):203–208.

20. Remouchamps VA, Vicini FA, Sharpe MB, Kestin LL, Martinez AA, Wong JW: Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for Hodgkin lymphoma. J Med Genet 2008, 45(3):142–146.

21. Menashe I, Rosenberg PS, Chen BE: Radiation therapy for patients treated with locoregional breast irradiation. Int J Radiat Oncol Biol Phys 2013, 81(1):83–90.

22. James ML, Lehman M, Hider RN, Jeffry M, Hickey BE, Francis DP: Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev 2010, (11):CD003865.

23. Hanner R, Thompson RF, Chen Y, Bernstein K, Kabarriti R, Skinner W, Chen BE: Genetic association analyses of radiation therapy and risk of breast cancer. Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008, 371(9618):1098–1107.

24. Goldsmith C, Haviland J, Tsang Y, Sydenham M, Yarnold J, Grp FT: Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009, 27(16):2638–2644.

25. Wahlin M, Rosenbeck P, Rubbe S, Heidenr F, Penegar S, Chandler I, Hodgson LM, MLH1-93G > A is a risk factor for MSI colorectal cancer. Carcinogenesis 2011, 32(8):1157–1161.

26. Halaby N, Pitsakis TM, Dueck AC, Suman V, Pierce L, Solin L, Solis M, Davidson N, Martin S, Kaufman P, Gette S, Dahnke SR, Perez EA: Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009, 27(16):2638–2644.

27. Halaby N: Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy. BMC Cancer 2014, 14:711.